• 1
    Hattori Y, Hottori S, Wang X, Satoh H, Nakanishi N, Kasai K. Oral administration of tetrahydrobipterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol2007;27:865870.
  • 2
    Barbier O, Pineda Torra I, Duguay Y, Blanquart C, Fruchart J, Glineur C, Staels B. Pleiotropic action of peroxisome proliferator-activated receptors in lipid metabolism and atheroslcerosis. Arterioscler Thromb Vasc Biol2002;22:717726.
  • 3
    Gervois P, Kleemann R, Pilon A, Koenig W, Staels B, Kooistra T. Global suppression of IL-6-induced acute phase response gene expression after in vivo chronic treatment with the peroxisome proliferator-activated receptor αactivator fenofibrate. J Biol Chem2004;279:1615416160.
  • 4
    Kowalski J, Okopien B, Madej A, Zielinski M, Belowski D, Kalina Z, Herman ZS. Effects of fenofibrate and simvastatin on plasma sICAM and MCP-1 concentrations in patients with hyperlipoproteinemia. Int J Clin Pharmacol Ther2003;41:241247.
  • 5
    Goya K, Sumitani S, Xu X, et al. Peroxisome proliferator-activated receptor α agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol2004;24:658663.
  • 6
    Yakubu MA, Nsaif RH, Oyekan AO. Peroxisome proliferator-activated receptor α activation-mediated regulation of endothelin-1 production via nitric oxide and protein kinase C signaling pathways in piglet cerebral microvascular endothelial cell culture. J Pharmacol Exper Therapeut2007;320:774781.
  • 7
    Capell WH, DeSouza CA, Poirier P, et al. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol2003;23:307313.
  • 8
    Playford DA, Watts GF, Best JD, Burke V. Effect of fenofibrate on brachial artery folw-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol2002;90:12541257.
  • 9
    He L, Zeng H, Li F, et al. Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobipterin in patients with hyperhomocysteinemia. Am J Physiol Endocrinol Metab2010;299:E1061E1065.
  • 10
    Wang G, Wei J, Guan Y, Mao J, Wang X. PPAR-γ agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism2005;54:590597.
  • 11
    Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X. PPAR-γ agonist improved arterial stiffness in type 2 diabetes patients with coronary artery disease. Metabolism2007;56:13961401.
  • 12
    Yu J, Zhang Z, Li Z, et al. PPARγ agonist improve coronary artery endothelial function in diabetic patients with coronary artery disease. J Int Med Res2010;38:8694.
  • 13
    Hozumi T, Yoshida K, Ogata Y, Akasaka T, Asami Y, Takagi T, Morioka S. Noninvasive assessment of significant left anterior coronary descending artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation1998;97:15571562.
  • 14
    Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med1999;340:115126.
  • 15
    Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein -1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation2001;103:25312534.
  • 16
    Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet2001;357:905910.
  • 17
    Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y. PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci2008;82:884891.
  • 18
    Li P, Shibata R, Maruyama S, Kondo M, Ohashi K, Ouchi N, Murohara T. Fenofibrate promotes ischemia-induced revascularization through the adiponectin-dependent pathway. Am J Physiol Endocrinol Metab2010;299:E560E566.
  • 19
    Hennuyer N, Tailleux A, Torpier G, Mezdour H, JC Fruchart, Staels B, Fiévet C. PPARα, but not PPARγ, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol2005;25:18971902.
  • 20
    Campisis R, Di Carli MF. Assessment of coronary flow reserve and microcirculation: a critical perspective. J Nucl Cardiol2004;11:311.
  • 21
    Aoun S, Blacher J, Safar ME, Mourad JJ. Diabetes mellitus and renal failure: Effects on large artery stiffness. J Hum Hypertens2001;15:693700.
  • 22
    Fukuda D, Yoshiyama M, Shimada K, et al. Relation between aortic stiffness and coronary flow reserve in patients with coronary artery disease. Heart2006;92:759762.
  • 23
    Ryan K, McCance DR, Powell L, McMahon R, Trimble ER. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis2007;194:e123130.
  • 24
    The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomized controlled trial. Lancet2005;366:18491861.
  • 25
    Inoue I, Goto S, Matsunaga T, et al. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism2001;50:311.
  • 26
    Okopien B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab2006;91:17701778.
  • 27
    Jin L, Caldwel RB, Li-Masters T, Caldwell RW. Homocysteine induces endothelial dysfunction via inhibition of arginine transport. J Physiol Pharmacol2007;58:191206.
  • 28
    Topal G, Brunet A, Millamvoye E, Boucher JL, Rendu F, Devynck MA, David-Dufilho M. Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. Free Radic Biol Med2004;36:15321541.
  • 29
    Wang G, Dai J, Mao J, Zeng X, Yang X, Wang X. Folic acid reverses hyper-responsiveness of LPS-induced chemokine secretion from monocytes in patients with hyperhomocysteinemia. Atherosclerosis2005;179:395402.
  • 30
    Dai J, Li W, Chang L, et al. Role of redox factor-1 in hyperhomocysteinemia-accelerated atherosclerosis. Free Radic Biol Med2006;41:15661577.